How much does cnn pay corpers

But they have invited along nations with a big stake in the Indo-Pacific as well, like India, like Australia, like South Korea, also South Africa has been invited.

So, it is really is an effort the way that they are describing it to bring together countries that value democracy, that try to find a way to head off the threats of countries like China, like Russia that would undermine these democratic values and principles by abuse of human rights, by theft of intellectual property, by cyber espionage, by manipulating elections.

Climate issue is a big one. But, also how to get ready for the next pandemic, how to prepare for that. So it is a host of issues that they are discussing here, but underneath it all, it's happening in the face of the pandemic, in the face of what's happening in India, and they hope that if this is a success in these few days, then the Summit and Cornwall with the real leaders, that can also go off -- with these COVID protocols, it can go off well. And to your point, a lot of important discussions to take place, too.

Nic Robertson, thank you so much for that. All right, let me bring you up to speed now with some of the other stories making headlines around the world. At least 23 people have been killed after an overpass carrying a subway train collapsed in Mexico City sending train cars onto the traffic below. Surveillance video caught the moment it happened late Monday evening, dozens of people are being treated in hospital.

Matt, great to have you with us. Clearly, we're interested in what on earth happened here. I believe it was a relatively new piece of the subway system. But what do we know about those that were injured and their status at this moment? Seventy nine people have been hospitalized as a result of this. Unfortunately, we know that included in the death toll as well as people who were hospitalized, some with serious injuries are children.

Children are included in both of those figures. In terms of what happened here, that's going to be the big question moving forward over the coming days and weeks. What we know is that it was about p. They were able to get a lot of people that were trapped out relatively quickly, but unfortunately, they weren't able to save everyone.

We actually saw several bodies being removed from the debris within the last several hours. But the concerning part about all of this, beyond just the deaths and the injuries would also be the fact that many people saw this coming.

This line was built by the Mexico City government and it was inaugurated back in , but in , there were structural problems identified with this line. More than half of the stations along this line were closed for structural repairs. There was damage during the earthquake. So this is a line that has had problems before, Julia, and so many people in this neighborhood and all across the city, really, this is huge news in Mexico right now, are saying how did this happen?

Something clearly went wrong. We don't know what went wrong, but there was a catastrophic collapse here, and so clearly something was at fault. That's going to be what investigators are going to try and determine over the next several days and weeks and maybe even months. More of that trial coming up on the show. Stay with us. One of its leading pharma firms is racing to find solutions. Zydus Cadila, also known as Cadila Healthcare has a vaccine in late stage trials.

It hopes to apply for emergency authorization later this month. He is Managing Director of Zydus Group. Sharvil, fantastic to have you on the show. Let's talk about that antiviral agent first, Virafin, I believe is the name. Just explain how it works. So, I am very, very excited with the results of our clinical study that we just got over and we got emergency use.

So you know, interferons are the naturally occurring proteins in the human body and for any kind of virus infection, the first line of defense is for the body to produce interferons, which removes the -- it stops the virus replication and allows the immune system to remove the virus.

I think this week could prove both in our in vitro and in vivo studies, so we did an in vitro study which showed that this is significantly more potent than any of the antivirus that are currently used for the treatment of COVID, so that was the one first positive thing. This treatment has always been used for hepatitis B and C, which are other viruses, so we knew that this works against multiple viruses.

Same is what we could prove -- and we did a patient study in India in moderate cases where we showed that we reduced the virus replication and removal by showing RT-PCR negative in eight days.

We showed a two-point important on the W. We showed less oxygenation requirement for the patients who were taking Virafin and also other symptoms were reduced and the number of days of hospitalization was reduced. All of that was done against standard of care and in India, standard of care includes treatments which are steroids, maybe remdesivir and others, and we have cohort analysis against all of these in conjunction with Virafin and using independently.

All in all, in all of the data, either we are equivocal or statistically significantly better, so that gives us the confidence that use of this in early treatment can help patients a lot. The beauty of this product is that it's a single dose which helps in terms of convenience of dosing and it can be given by any medical practitioner.

So it stops the shedding of the virus, it helps the body's own immune system fight back and protect itself as well. Just give us a sense, if you can, how quickly -- once somebody has been diagnosed with COVID, how quickly -- what's the window that they get this vaccine? And then, I guess, the most important question is manufacturing. How quickly can you produce this and start helping people and saving lives as soon as possible?

So I would assume that they were at least three to five days post infection and, you know, it being a very strong antiviral agent and we know that the virus is active for the first eight to 10 days, the rate of treatment, this would be there as soon as possible, one should use this because it is an antiviral agent and using this later has less of a benefit versus using it earlier when the virus is not replicated enough and not destroyed the epithelial cells and created other problems.

And the second part to your question related to the capacity, so you know, it is a biological product. We have been manufacturing this, but we have significantly put in capacities and investment to scale this up. We are going to be making it available immediately for 50, patients in this month, but in the following month onward, we believe we can reach up to 10 lakh patients or one million patients per month.

Our hope is by end of June we can achieve one million per month run rate. I mean, I compare it to the number of cases out there and it feels like a drop in the ocean, but I guess if you're giving it to the most sick patients, if you can catch them early enough, then that's the important part. Let's talk about vaccines as well because you obviously have and are in Stage 3 or Phase 3 trials with your own vaccine candidate.

We're expecting results -- fingers crossed -- this month. What can you tell us just even in these early stages about the efficacy, even if it's only with regards Phase 2? This is one vaccine where Zydus has developed this from scratch. We have been doing all of the technology development all the way to scale up all the way to now, clinical trial.

I'm also very happy to say that this is by far the largest clinical trial done in our country where we have covered 28, volunteers for the administration of this vaccine. So, it is by far one of the largest trials that we have done and we have been good on recruitment, so in spite of vaccines being there, people have shown faith in terms of coming up for the clinical work on this.

So, I thank everybody for doing that. But more importantly, I think what we like about the vaccine is that it is -- the platform is an extremely safe platform, well established. So this vaccine is very safe in terms of multiple dosing. It is stable at 25 degrees for at least four months. So you know, in a country like India, it is important. We have gone through multiple cycles and has shown good data in terms of it not going to waste.

Again, the beauty of the vaccine is, it will be that it is a needle-free dosing. So it takes away a lot of fears for young people and people who have phobia related to needles and vaccination. So again, it helps on that, and we have a whole new technology to deliver the vaccine for that.

So all of that has been good. Our Phase 2 efficacy -- in Phase 2, you don't really see efficacy, but you see immunogenicity. We showed comparable immunogenicity to most of the peers that are there in the approved vaccines that are in there in the country.

Efficacy is something that we can only get to see post Phase 3, which we're confident of that in May we can achieve that event number. And as soon as we do that, we will file for our emergency use authorization.

Are you also focused on the ability to adapt this if necessary to fight specific variants? Or can you tell us anything about its -- I know, you're saying you can't give efficacy numbers, but the sense that it can fight the variants that we're already seeing? So I think two important things. One is, I believe that in this clinical study, this will be the most truly represented clinical study, because we have, you know, variants of critical nature in India and multiple of them.

And all our event data will be a subset of many of these events of infections happening. So I believe this would be one of the true deflections of how this vaccine can work against a plethora of variants that are there in the country. What is also good about this is that it definitely neutralizes many of the viruses that are there. But more importantly, this platform is very scalable, and very, very changeable to the new variants.

So in fact, against the British variant, the South African variant, the Brazilian as well as the new Indian mutant variant, we have already finished three upgradations to the platform.

We already finished animal studies on them. So you know, we would be able to, not in a long time, but in a very short period of time repurpose the vaccine with the new variants, whichever becomes dominant. Sharvil, very quickly, another vitally important question: cost of both the antiviral and this vaccine, can you give us just a comparison or a sense of how much this will cost?

Because clearly there will be -- I'm sure people in India watching this and just wondering how they get access, whether they will be able to get access? PATEL: So yes, that's a very important question to our country, access and affordability is paramount in terms of how one can get to use the medicines. So on our Virafin, we have committed and promised that to any of the standard of care, it will be substantially cheaper.

It will be at least less than half of one-fifth of the current treatments that are there for patients who are taking remdesivir and hospitalization kind of efforts. So we believe that we will bring it at very affordable pricing.

And as I said, again, it's a single dose. With respect to the vaccine, definitely our aim is that we will bring it at an affordable price. If you look at our track record in the last one year, whether it was hydroxychloroquine, we were the largest manufacturers and distributors of hydroxychloroquine. We brought it below the price. It was remdesivir. We are today the lowest priced remdesivir in the country by a magnitude of threefold.

If you look at dexamethasone, which is of the steroids that is used, it is the cheapest corticosteroid available in the country. So we will definitely work on it to make sure we make it affordable, but obviously, it has to make sense in terms of us being able to recoup all our investment.

You give us hope though, Sharvil. I'll let you go because you and your team have a lot of work to do, I know. More to come. The Wall Street bulls however taking a pause after recent record runs as you can see there. We are lower in early trade this morning. European airline stocks are gaining altitude though as the E. Vaccinated vacationers, that's a tough one to say. Word too that the number of U. But once again, context is everything.

Air travels still some 35 percent below peak levels in the United States. And a pretty cute visitor, if we have pictures of this, I think Baby Yoda actually run -- look.

Now that's cute. That may be the best ring bell ever. There we go. Baby Yoda. May the force be with you. All right, another bite of the Apple. Day two of the Epic-Apple trial set to begin here in the United States. At the center, the core of this lawsuit, the 30 percent slice -- fee -- Apple charges developers on sales made through apps. Clare Sebastian, joins me now. Sorry, Clare, I couldn't help myself. No more puns. I promise. It was quite fascinating, though, to listen to what the Epic Game CEO was saying because he was painting this picture of Apple having this huge hold, this monopoly, and of course, under U.

And if you keep out competition, and that ultimately harms the consumer. He's got a case to make. And what we saw yesterday, Julia, along with quite a few internal e-mails that both sides produced that, frankly, didn't make either side look very good, was this sort of framing exercise.

The question of whether Apple's App Store is a market in its own right, or is it part of a broader market? Now obviously, Epic was to make the argument that the App Store is a market in its own right, and therefore Apple shouldn't be allowed to set all the rules.

They produced a number of different internal e-mails, one in particular from Apple executive Eddie Cue, where he talks about getting people hooked into the ecosystem, so they never leave.

This gets back to the idea of abuse of monopoly power that Epic is trying to prove. Apple, of course, says no, that's not the case.

They are part of a broader market, particularly in gaming. They made the point that consumers have a lot of choice about where they go to play their games.

They pointed out that Epic pays the 30 percent commission or thereabout to have its games on consoles like Xbox and PlayStation, though Tim Sweeney made the point that that's a different business model.

So much more to come, Julia, but expect this framing exercise to remain at the center of the arguments here. Do you think that PR campaign backfires, Clare? I was certainly a risky move from Epic to do that last summer, to basically publicly go out there and breach the terms of the contract that they had already signed with Apple, and Apple is going to continue to use this against them. If you look at the opening statements that the slides that Apple produced yesterday, there was another e-mail, this one from Tim Sweeney, the CEO of Epic to a Microsoft executive in early August.

He says, "Epic has plans for August that will provide an extraordinary opportunity to highlight the value proposition of consoles in PCs in contrast to mobile platforms. They are trying to paint this as a sort of profit move from Epic whereas Epic says this isn't about profits.

This is about getting Apple to change its way. So I think, look, this was very risky. Apple is going to continue probably to use this to undermine Epic as this trial continues.

Clare Sebastian, thank you for that. Okay, after the break, we've had it all before, your call is important to us. But is it? After the break, MessageBird on a mission to end hanging around on hold?

Well, my next guest thought there has to be a faster way to get good customer service considering how many communication tools are available. Robert, great to have you on the show. So you facilitate better communications between businesses and their customers, but you're also trying to do it in the most efficient way possible.

Nice to meet you. And I couldn't have done the intro better myself. So I think you explained it very well. Look at MessageBird, we want to make talking to a business feel as easy and natural as talking to your friends and family.

So we like consumers, essentially, all of us talk to a business on the channel that they prefer, which could be things like Instagram, or WhatsApp, or SMS, or email, or even being on the phone.

But it is right, essentially, our premise is, we want to make communication way more efficient, I want to stop people being on hold for bad customer service. Very few. VIS: It is true, and that's very unfortunate. And this is essentially exactly what we're trying to fix. So today, most of the interactions are still happening on e-mail and voice, which isn't a very efficient way to communicate with a business, and we just want to live in a world where you can text with a business and that's essentially what we're trying to make happen.

And we're providing as we are building the technology on the back end, to provide that to businesses, because you're right, it's very complicated. And part of the reason why we're not able to text the businesses today that has a lot to do with their internal infrastructure and backend technology that doesn't allow them to do that.

So we're essentially selling that technology to the business so that with MessageBird, they can now talk to their customers on any channel, and they don't have to be on hold. Give me that weld as soon as possible, please. VIS: Let's do it.

And yet when I look at -- and I mentioned it in the into -- your acquisition trail, Spark Post, predictive e-mail intelligence platform, I mean, I can see that this gives you a foothold in the United States, but there will be people going, hang on a second, aren't we trying to move away from communications on e-mail? Are you saying here, actually, you still see e-mail as being a crucial part of the way that e-mails interact -- companies interact with their customers? VIS: It is. So e-mail is still -- I mean, today, it's the most important channel that people communicate with businesses on and we think e-mail is very powerful also for the future.

There's new technologies coming out on e-mail, like AMP, which makes it much more like an application. But what we're after here is actually very simple. I mean, first of all, we're now the largest business to consumer interaction company in the world. We do over four and a half trillion interactions to customers, and think about that, that's a thousand billion. These are a lot of interactions that we're sort of doing, which I think is very powerful to do our business.

E-mail is still being the dominant way we talk to businesses today, it makes it super important. I think the challenge is, how do we get an e-mail that really provides the right context so we find it valuable? I think from a consumer perspective, we think about e-mail as something that lands in your SPAM box and we think about e-mail as something that provides a ton of value to you.

It just needs to have the right message. So that's what we help businesses do. Talk on WhatsApp, talk on the phone, talk on e-mail, but it's really about the context and making things more efficient. That's the opportunity we are after. What makes you better than them, particularly as you tackle a new market like the United States?

Or is the market simply big enough to have more? VIS: Who is Twilio again? VIS: I would almost leave it there. Look as a company, I think -- and look, you'll probably hear a lot of founders say this, but like we focus on our customers. Our customers, they have all the answers that we would ever need. They tell us what they would like from us, how they want to make things more efficient, and you know what, they pay our bills. Brothel offers free entry, but there's a catch. Video from Poland-Belarus border shows thousands caught in standoff.

Satellite images show China's new aircraft carrier with advanced technology. The building, located on Gerald Road in the city's affluent Ikoyi neighborhood, is a construction site for luxury apartments. It is unclear how many were inside when it fell, but people were feared to be trapped. Search and rescue operations from multiple agencies continued through the night and into Tuesday morning.

It did not say how many people are currently missing. Apata said the building has been under construction for the past two years and that the developer was at the site meeting with prospective buyers earlier on Monday.

Read More. Three people have since been rescued from the collapse, according to a statement from the Lagos State government, which added that the city's rescue unit, fire service and ambulance service was on the scene.

The investigation into the cause of the collapse is ongoing, and officials on the ground are evaluating possible damage to the surrounding structures, the statement said. Muhammad, a civil servant, told CNN he was in his office next door when the high rise came down. So, I looked through the window, only to see the building collapsing floor after floor. And of course, we all ran to safety. It took a while for rescue services to arrive at the scene.

Hours after the collapse, hundreds of people were milling around the site, helplessly surveying slabs of concrete piled high in a heap. Locals were digging through the wreckage by hand. Some in the crowd were furious that an official emergency response had not started.

The building collapsed in the affluent Ikoyi neighborhood in Lagos. Instead, rescue efforts were being carried out by passersby such as Rashid Olamilekan, who told CNN he had pulled three construction workers from the rubble.